AD_____

Award Number: DAMD17-02-1-0586

TITLE: Tumor-Secreted Autocrine Motility Factor [AMF]: Causal Role in an Animal Model of Cachexia

PRINCIPAL INVESTIGATOR: John M. Chirgwin, Ph.D.

CONTRACTING ORGANIZATION: University of Virginia
Charlottesville, Virginia 22904

REPORT DATE: August 2003

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE	3. REPORT TYPE AND DATES COVERED
	August 2003	Annual (1 Aug 2002 - 31 Jul 2003)

4. TITLE AND SUBTITLE
Tumor-Secreted Autocrine Motility Factor [AMF]: Causal Role in an Animal Model of Cachexia

5. FUNDING NUMBERS
DAMD17-02-1-0586

6. AUTHOR(S)
John M. Chirgwin, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
University of Virginia
Charlottesville, Virginia 22904

E-Mail: jc3qb@virginia.edu

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSORING / MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 Words)

Purified mouse autocrine motility factor/phosphoglucose isomerase was found to cause weight loss (cachexia) after 3 days of 3X daily intraperitoneal injection, which was accompanied by significant increases in serum concentrations of the factor. This is a simpler animal model than originally proposed structure of the protein complexed with inhibitor has been soved by x-ray crystallography and published. Mutant forms of the protein have been prepared. Experiments are underway to improve the purity of the recombinant protein and to characterize the effects of the factor on both intact animals and on a mouse muscle cell line in vitro.

14. SUBJECT TERMS
Cancer cachexia, muscle proteolysis, phosphoglucose isomerase autocrine motility factor, animal model

15. NUMBER OF PAGES
26

16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Unlimited

Table of Contents

Annual Progress Report, year 01 John M. Chirgwin Ph.D.

Award DAMD17-02-1-0586

Tumor Secreted AMF: Causal Role in an Animal Model of Cachexia

INTRODUCTION:

Update on cancer cachexia, August 2003. Cancer cachexia has three clinical features (Fearon & Moses, 2002; Tisdale, 2002): 1) loss of appetite (anorexia), which probably has a central nervous system component, 2) nutritional mal-absorption, and 3) muscle and fat wasting caused by tumor-stimulated factors (Kotler, 2000; Tisdale, 2000). This application focuses on the 3rd component. A number of factors have been proposed to cause cancer cachexia (Matthys & Billiau, 1997; Tisdale, 1998). These fall into two classes: primary ones produced by the cancer cells themselves and secondary ones, which are inflammatory factors released by the host in response to the tumor. The existence of tumor-produced factors has been long known (Norton et al, 1985), but few such factors have been identified at the molecular level. In addition, cachexia is typical of AIDS, rheumatoid arthritis (Roubenoff et al, 1992), and other diseases, as well as cancer. Despite extensive characterization of cytokine involvement in cachexia, progress in treatment of cancer cachexia has been limited (Argiles et al, 2001; Nelson, 2000), and treatments aimed at inhibiting the actions of host-produced inflammatory mediators have not been widely successful (von Haehling et al, 2002; Inui, 2002). Lack of progress in the area is unfortunate, given the tremendous benefit patients with advanced cancer would receive from effective treatment of cachexia to improve their quality of life and postpone mortality.

Biochemical mechanisms of cachexia have been explored in vivo and in vitro. Lipid wasting (Kalra & Tigas, 2002), changes in the insulin-like growth factor pathways (Crown et al, 2002), and alterations in appetite and caloric balance (Schwartz & Morton, 2002) all contribute to cancer cachexia. However, muscle wasting is the facet which is currently best understood (Tisdale, 2001), as well as being amenable to scientific study and, potentially, to therapeutic intervention. The severe skeletal muscle wasting characteristic of cancer cachexia appears to be due to activation of proteasomal degradation of structural proteins in muscle (Hasslegren & Fisher, 2001; Whitehouse et al, 2001: Giordano et al, 2003). Less understood are the primary factors released by tumor cells responsible for initiating the muscle wasting, but progress in the last several years has identified several candidates: proteolysis-inducing factor (PIF), a sulfated polypeptide isolated from urine of cachectic patients (Cabal-Manzano et al, 2001; Lorite et al, 2001), and myostatin (Zimmers et al, 2002).

In addition, the osteolytic factor PTHrP causes cachexia when systemically elevated. However, this is accompanied by humoral hypercalcemia of malignancy (Guise et al, 1992; Guise et al, 1996; Guise & Mundy, 1998), and there may be direct cachectic effects of PTHrP on the kidney, independent of hypercalcemia (Iguchi et al, 2001). Complicating the role of PTHrP is its contribution to osteolytic bone metastases by breast cancer. The MDA-MB-231 cell line causes PTHrP-dependent bone metastases (Guise et al, 1996). Animals with bone metastases due to this tumor become profoundly cachectic but without significant increases in circulating concentrations of PTHrP (Yin et al,1999). Recent work also implicates cachectic effects on

mitochondria by activation of uncoupling proteins (UCPs), especially UCP-3, which results in ATP energy wasting (Tisdale, 2002; Glass, 2003).

Role of the proteasome. Skeletal muscle proteolysis in cachexia is probably due to increased activity through the proteasomal pathway, rather than via lysosomes or soluble sarcoplasmic proteases Lazarus et al, 1999). It has recently been observed that certain cancer treatment protocols can either enhance (Tohgo et al, 2002) or inhibit this muscle degradation (Tilignac et al, 2002) pathway. Thus, cancer chemotherapy may alter cachexia in patients. Omega-3 fatty acids and other eicosanoids can regulate the activity of the proteasome (Whitehouse et al, 2001), providing a biochemical rationale for the dietary treatment of cancer cachexia (Ross & Fearon, 2002; Jho et al, 2002). It is not yet clear that activation of proteasomal degradation is the central or the only pathway for muscle wasting in cancer cachexia (Hasslegren et al, 2002; Jagoe & Goldberg, 2001; Glass, 2003; Lecker, 2003). In addition to their effects on the proteasome, ω-3 fatty acids decrease expression of ras, AP-1, and cycloxygenase-2 (Hardman, 2002).

BODY OF PROGRESS REPORT

Timetable: The award of this grant was made just as the Principal Investigator was moving from the University of Texas to the University of Virginia. Initial work was commenced upon arrival in Charlottesville Virginia in October 2002. A new research associate was recruited to work on this project, Ms. Lisa Wessner, who is an experienced molecular biologist. She has learned all of the techniques specific to the project, which has been fully active since approximately January 1 of the current year. Thus, this progress report represents work carried out over a seven-month period. All animal procedures are now in place and approved by the insitution (an extremely slow process).

The revised application contained **3 Specific Aims and 9 Tasks** in the revised Approved Statement of Work.

Under Aim1, **Task 1** is complete and **Task 2** is underway. Our initial data (**Table 1**) showed that Alzet minipumps did not achieve useful increases in steady-state blood concentrations of mouse PGI/AMF, even when the pumps were loaded with 10mg/ml protein solution. However, initial experiments (**Figure 1**), demonstrate that a simpler approach successfully gave substantially increased steady-state blood concentrations of mouse PGI/AMF. In this experimental protocol, animals were given the factor as sterile intraperitoneal (i.p.) injections of protein in PBS at 8 AM, noon, and 4 PM. Blood levels of PGI/AMF were measured at the 4PM time. **Figure 1** indicates that the injected AMF/PGI was entirely cleared from the blood stream by 24 hours. In this experiment, there was a decrease in body mass consistent with a significant cachectic effect of the injected factor. This response is equivalent to that seen by the Tisdale group in their experiments with PIF, a sulfated peptide purified from urine of cachectic animals (Todorov et al, 1997; Lorite et al, 1998). When injected into animals the peptide reproduced cachexia. No cDNA sequence for PIF has been published, but a commercial patent (Akerblom & Murry, 1998) describes a cDNA, which includes the reported N-terminal sequence of PIF (Todorov et al, 1997). This sequence does not give any significant matches in the present Genbank database of human and mouse sequences when subjected to a BLAST search (Chirgwin, unpublished), suggesting that PIF/HCAP may be produced by an opportunistic

microorganism. Chlamydial infection, for example, may contribute to cachexia in patients with AIDS, and in general patients with cachexia are immunocompromised. Recent works shows that PIF can activate, through NF-6B, endothelial cell expression of IL-6 and IL-8 (Watchorn et al, 2002), the later of which is produced by breast cancer cells and can directly enhance bone metastases (Bendre et al, 2002).

On the basis of the initial results, shown in **Figure 1**, the remaining experiments for Tasks 2, 4, 7 and 8 will be carried out by direct i.p. injection of recombinant protein 3X per day. An initial experiment to study clearance of a single injection of purified protein (**Figure 2**) suggests that between 10 and 100ug/ injection should be sufficient, which would be at least 5X less than the amount used in Figure 1. We are presently determining the minimum effective dose to give progressive weight loss accompanied by increased steady-state blood concentrations. As soon as this is determined, we will test whether the number of doses (presently 9 = 3/day x 3 days) can be decreased. This modified approach eliminates the need for animal surgery to implant minipumps and permits the experiments to be of one week or less duration. The number of animals remains unchanged. The results also indicate that expensive Balb/c nude/nude mice are not needed for the cachectic response.

Tasks 3 and 4 have not been initiated.

Tasks 5 and 6 have been started. The catalytically inactive mutant E357A has been constructed, expressed and purified. The role of isomerase (PGI) activity in relation to autocrine motility factor (AMF) activity remains a central controversy in the field, with two papers reporting AMF activity as a property of bacterial PGI (Sun et al, 1999; Chou et al, 2000). In addition PGI catalytic activity has been suggested to be essential to AMF cytokine activity. These experiments involved adding PGI active site inhibitors at mM concentrations into bioassays, in which the AMF/PGI factor was added at nM concentration. The million-fold excess of inhibitor over factor could easily have resulted in non-specific inhibitory effects (e.g., Lagana et al, 2000). In fact, more recent experiments have suggested the opposite (Tsutsumi et al, 2003). Much of the AMF cytokine work has not taken into account the current knowledge of PGI structure. We (Davies et al, 2003) and others (Arsenieva & Jefferey, 2002), have shown that ligand binding to mammalian PGIs results in only very small conformational changes in the surface of the protein away from the active site (where binding to the AMF receptor almost certainly takes place).

In **Task 6**, we have encountered a substantial obstacle. The recombinant proteins upon which all of the experiments in the proposal rely are expressed in the bacterium *Escherichia coli*. Gram negative bacteria are a prime source of inflammatory endotoxins collectively called lipopolysaccharides (LPS). We have assayed all of our AMF/PGI preparations with an endotoxin assay kit using amoebocyte lysates from Sigma Chemical Co (St. Louis). By this assay all of our preparations were LPS-free. However, the standard curves with the Sigma kit gave inconsistent results, and we have switched to a parallel assay from BioWhittaker, CA). By this assay, our preparations (such as that used in the supplied preliminary data) were not LPS-free, although the level of contamination was that considered by other investigators to be relativelylow (Bausinger et al, 2002). LPS contamination has been realized to cause cytokine-like artifactual responses in mammalian cells treated with bacterially expressed proteins (Gao & Tsan, 2003; Bausinger et al, 2002; Colangeli et al, 1998; Ozaki et al, 1989).

Preparation of LPS-free AMF/PGI. We have tested several different types of metal chelates resins for purification of His6-tagged protein. Standard NiNTA agarose gives material that appears substantially pure by Laemmli gel with Coomassie blue staining (**Figure 3**). The

columns yielded AMF/PGI preparations with equivalent amounts of LPS contamination. Addition of washing steps with nondenaturing detergents, such as sodium deoxycholate or triton X-100 was also ineffective. A published procedure for this purpose, involving washing the column with cold isopropanol (Kees et al, 2000) was totally unsatisfactory. The isopropanol interferes with the column flow and was entirely without effect on reduction of the endotoxin contamination of the eluted protein.We have been successful in removing LPS from AMF/PGI preparations by adding a second chromatography step of passing the purified protein in PBS over a column of immobilized polymyxin B (Detoxigel, Pierce Chemical Co). Polymyxin B is a cyclic oligopeptide antibiotic effective against gram-negative bacteria; it binds bacterial lippolysaccharides with high affinity. The Detoxigel step results in loss of almost all of the applied AMF/PGI and we have been able to purify only about 1mg of protein in this manner. Prior to Detoxigel chromatography the contamination of AMF-PGI was 1.34 parts per million (ppm) on a weight per weight basis, using the conversion factor of 1 I.U. of endotoxin = 83 pg (Kees et al, 2000). After chromatography , the contamination was 0.079 ppm, representing a 60-fold purification. The material prior to Detoxigel purification contains 90 I.U./mg of AMF-PGI, while 60 I.U./mg is defined as low endotoxin contamination of r(hu)hsp 70, which lacks activity on monocytes in vitro (Bausinger et al, 2002).

We have tested our most highly purified AMF-PGI in chemotaxis assays with two mouse monocyte/macrophage cell lines. The data shown in **Figure 4** , show that the material was entirely negative in these two assays. These experiments were conducted in collaboration with Prof. Lynda Bonewald, University of Missouri Kansas City School of Dentistry.

We are currently testing two further strategies: 1) initial binding to and washing of AMF/PGI to the Ni-NTA agarose affinity chromatography resin in the presence of soluble polymyxin B to dissociate the contaminating LPS from the resin-bound AMF/PGI; 2) active-site affinity chromatography as originally described by Phillips et al (1976). The active site of the protein binds to washed phosphocellulose and specific elution is accomplished with glucose 6-phosphate substrate. We will also test whether combining 1) and 2) is effective. We believe that this is an important problem to solve. Unrealized LPS contamination has resulted in major published artifacts with other proteins. We suspect that the AMF activity reported for bacterial PGI (Sun et al, 1999; Chou et al, 2000) is probably due to LPS contamination, a possibility supported by recent, more careful work (Amraei & Nabi, 2002), which has invalidated the earlier conclusions.

We believe that the additional work proposed within this task could have general applicability for the field of biological activity of bacterially-expressed proteins. If the new purification steps are not successful, we will use the inefficient approach of Detoxigel chromatographt or of injection of less pure AMF/PGI which has been mixed with sterile USP-grade polymixin B (Sigma).

An in vitro model of muscle wasting was recently described by Gomes-Marcondes et al (2002) have described, in which PIF directly stimulates the hydrolysis of radiolabeled muscle protein from the myoblast/myotube cell line C2C12 in vitro. This model provides an efficient system for biochemical assay of circulating factors which act directly on muscle cells. The C2C12 cell line progresses through a skeletal muscle differentiation program in vitro. A mediator of this process is MyoD, which is in turn regulated by the transcription factor NF-6B. The cachectic cytokines TNF" and IFN-(may cause muscle wasting by suppressing MyoD expression (Guttridge et al, 2000) in C2C12 cells. PIF can regulates transcription via NF-6B and

STAT2 (Watchorn et al, 2001) while the activity of NF-6B is regulated by the proteasome (Langen et al, 2001). The factor also plays a central role in multiple myeloma (Berenson et al, 2001; Hideshima et al, 2002). Suppression of NF-6B attenuates cachexia and metastasis in several mouse tumor models (Arlt & Schafer, 2002). Thus the NF-6B transcription factor may also be a target for anti-cachexia treatments, while itself being one of the mediators of the actions of proteasome inhibitors (Mitch & Price, 2000; Adams, 2001; Tisdale, 2002a).

We have attempted to replicate the Gomes-Marcondes model, although using IL-6 as an inducer of cellular proteolysis, since PIF is unavailable. We conclude that the model is probably acceptable as a means of analyzing responses in vitro to factors which stimulate muscle wasting in vivo. However, the model is technically unsatisfactory. Inspection of the original paper reveals large statistical errors, with large n values of 8 or greater needed to achieve statistical significance with small changes in total protein. We believe the model can be substantially improved by analyzing protein wasting by a more traditional analysis using trichloracetic acid precipitation to distinguish high molecular weight labeled protein from the soluble oligopeptides released by stimulated proteolysis. Similar approaches have been applied by other to C2C12 protein degradation (Taylor et al, 2001; Thompson et al, 1996; Fernandez & Sainz, 1997), although not in the context of assaying cachectic factors.

This is a supplemental experiment within task 2. If successful, the methodology would permit analysis of muscle-targeting cachectic factors in vitro, decreasing the future need for animal experiments.

KEY RESEARCH ACCOMPLISHMENTS:

1) Animal model of direct i.p. injection of AMF/PGI established.
2) Preliminary validation of central hypothesis obtained: Injected AMF/PGI caused progressive weight loss of 10% over the course of 4 days in individual mice.
3) Mutant mouse AMF/PGI constructed, expressed, and purified
4) Unsuspected contamination of AMF/PGI with inflammatory bacterial endotoxin detected. Improved purification protocol under development.
5) Crystal structure of mammalian AMF/PGI with active-site-bound ligand solved and published.

REPORTABLE OUTCOMES:

One manuscript published:

Davies C, Muirhead H, Chirgwin J (2003). The structure of human phosphoglucose isomerase complexed with a transition-state analogue. Acta Crystallogr D Biol Crystallogr 59:1111-1113

Four manuscripts in press accepted for publication which include reviews of the contributions of bone metastases to cancer cachexia:.

Chirgwin JM, Guise TA. Role of TGFb in osteolytic bone metastases. Clin Orthop, in press, 2003.

Chirgwin JM, Guise TA. Bisphosphonates in prostate cancer bone metastases. Semin Oncol, in press, 2003.

Chirgwin JM, Guise TA. Molecular mechanisms of cancer metastases to bone. Curr Opin Orthop, in press, 2003.

Guise TA, Chirgwin JM. Biology of bone metastases. Chapter in Diseases of the Breast, 3rd edition. Harris, Lippman, Morrow, and Osborne (eds). Lippincott Williams & Wilkins, accepted for publication, 2003.

CONCLUSIONS

Purified mouse autocrine motility factor/phosphoglucose isomerase was found to cause weight loss (cachexia) after 3 days of 3X daily intraperitoneal injection, which was accompanied by significant increases in serum concentrations of the factor. This is a simpler animal model than originally proposed. Thus the main hypothesis of the original proposal appears to be correct. Progress in the first (partial) year is on track, despite relocation of the laboratory from University of Texas to University of Virginia. Statistical validation of the initial animal model observations will be carried out in year 02

Structure of the protein complexed with inhibitor has been solved by x-ray crystallography and published. Mutant forms of the protein have been prepared. Experiments are underway to improve the purity of the recombinant protein and to characterize the effects of the factor on both intact animals and on a mouse muscle cell line in vitro.

COMPREHENSIVE LIST OF REFERENCES:

Adams J (2001). Proteasome inhibition in cancer: development of PS-341. Semin Oncol 28:613-619

Akerblom IE, Murry LK (1998). Human cachexia associated protein. U.S. Patent 5,583,192, issued to Incyte Pharmaceuticals, California

Argiles JM, Meijsing SH, Pallares-Trujillo J, Guirao X, Lopez-Soriano FJ (2001). Cancer cachexia: a therapeutic approach. Med Res Rev 21:83-101

Arlt A, Schafer H (2002). NFkappaB-dependent chemoresistance in solid tumors. Int J Clin Pharmacol Ther 40:336-347

Arsenieva D, Jeffery CJ, 2002. Conformational changes in phosphoglucose isomerase induced by ligand binding. J Mol Biol 323:77-84

Baumann M, Kappl A, Lang T, Brand K, Siegfried W, Paterok E (1990). The diagnostic validity of the serum tumor marker phosphohexose isomerase (PHI) in patients with gastrointestinal, kidney, and breast cancer. Cancer Invest 8:351-356

Bendre MS, Gaddy-Kurten D, Mon-Foote T, Akel NS, Skinner RA, Nicholas RW, Suva LJ (2002). Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res 62:5571-5579

Berenson JR, Ma HM, Vescio R (2001). The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin Oncol 28:626-633

Black K, Garrett IR, Mundy GR (1991). Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinol 128:2657-2659

Bodansky O (1954). Serum phosphohexose isomerase in cancer II: an index of tumor growth in metastatic carcinoma of the breast. Cancer 7:1200-1226

Cabal-Manzano R, Bhargava P, Torres-Duarte A, Marshall J, Bhargava P, Wainer IW (2001). Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br J Cancer 84:1599-1601

Caffier H, Brandau H (1983). Serum tumor markers in metastatic breast cancer and course of disease. Cancer Detect Prev 6:451-457

Cahlin C, Korner A, Axelsson H, Wang W, Lundholm K, Svanberg E (2000). Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res 60:5488-5493

Callander NS, Roodman GD (2001). Myeloma bone disease. Semin Hematol 38:276-285

Capparelli C, Kostenuik PJ, Morony S, Starnes C, Weimann B, Van G, Scully S, Qi M, Lacey DL, Dunstan CR (2000). Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 60:783-787

Carbo N, Lopez-Soriano J, Costelli P, Busquets S, Alvarez B, Baccino FM, Quinn LS, Lopez-Soriano FJ, Argiles JM (2000). Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. Br J Cancer 83:526-531

Crown AL, Cottle K, Lightman SL, Falk S, Mohamed-Ali V, Armstrong L, Millar AB, Holly JM (2002). What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? Clin Endocrinol (Oxf) 56:723-733

Cher ML (2001). Mechanisms governing bone metastasis in prostate cancer. Curr Opin Urol 11:483-488

Chirgwin JM, Guise TA (2000). Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 10:159-178

Colangeli R, Heijbel A, Williams AM, Manca C, Chan J, Lyashchenko K, Gennaro ML (1998). Three-step purification of lipopolysaccharide-free, polyhistidine-tagged recombinant antigens of Mycobacterium tuberculosis. J Chromatogr B Biomed Sci Appl 714:223-235

Coleman RE, Rubens RD (1987). The clinical course of bone metastases from breast cancer. Br J Cancer 55:61-66

Crown AL, Cottle K, Lightman SL, Falk S, Mohamed-Ali V, Armstrong L, Millar AB, Holly JM (2002). What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? Clin Endocrinol 56:723-733

Davies C, Muirhead H, Chirgwin J (2003). The structure of human phosphoglucose isomerase complexed with a transition-state analogue. Acta Crystallogr D Biol Crystallogr 59:1111-1113

De La Mata J, Uy HL, Guise TA, Story B, Boyce BF, Mundy GR, Roodman GD (1995). Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 95: 2846-2852

Draghia-Akli R, Hahn KA, King GK, Cummings KK, Carpenter RH (2002). Effects of plasmid-mediated growth hormone-releasing hormone in severely debilitated dogs with cancer. Mol Ther 6:830-836

Endo K, Katsumata K, Iguchi H, Kubodera N, Teramoto T, Ikeda K, Fujita T, Ogata E (1998). Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia. J Bone Miner Res 13:1378-1383

Esper PS, Pienta KJ (1997). Supportive care in the patient with hormone refractory prostate cancer. Semin Urol Oncol 15:56-64

Fearon K, Moses A (2002). Cancer cachexia. Int J Cardiol 85:73-81

Fernandez C, Sainz RD (1997). Pathways of protein degradation in L6 myotubes. Proc Soc Exp Biol Med 214:242-247

Giordano A, Calvani M, Petillo O, Carteni' M, Melone MR, Peluso G (2003). Skeletal muscle metabolism in physiology and in cancer disease. J Cell Biochem 90:170-186

Glass DJ (2003). Molecular mechanisms modulating muscle mass. Trends Mol Med 9:344-350

Gomes-Marcondes MC, Smith HJ, Cooper JC, Tisdale MJ (2002). Development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor. Br J Cancer 86:1628-1633

Guise TA, Chirgwin JM, Favarato G, Boyce BF, Mundy GR (1992). Chinese hamster ovarian cells transfected with human parathyroid hormone-related protein cDNA cause hypercalcemia in nude mice. Lab Invest 67:477-485

Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR (1996). Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98:1544-1549

Guise TA, Mundy GR (1998). Cancer and bone. Endocr Rev 19:18-54

Guttridge DC, Mayo MW, Madrid LV, Wang C-Y, Baldwin AS Jr (2000). NF-6B-induced loss of MyoD messenger RNA: Possible role in muscle decay and cachexia . Science 289: 2363-2366

von Haehling S, Genth-Zotz S, Anker S, Volk H (2002). Cachexia: a therapeutic approach beyond cytokine antagonism. Int J Cardiol 85:173-183

Hardman WE (2002). Omega-3 fatty acids to augment cancer therapy. J Nutr 132(11 Suppl):3508S-3512S

Hasselgren PO, Fischer JE (2001). Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Ann Surg 233:9-17

Hasselgren PO, Wray C, Mammen J (2002). Molecular regulation of muscle cachexia: it may be more than the proteasome. Biochem Biophys Res Commun 290:1-10

Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC (2002). NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277:16639-16647

Iguchi H, Onuma E, Sato K, Sato K, Ogata E (2001). Involvement of parathyroid hormone-related protein in experimental cachexia induced by a human lung cancer-derived cell line established from a bone metastasis specimen. Int J Cancer 94:24-27
Inui A (2002). Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 52:72-91

Jagoe RT, Goldberg AL (2001). What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr Opin Clin Nutr Metab Care 4:183-190

Jho DH, Babcock TA, Tevar R, Helton WS, Espat NJ (2002). Eicosapentaenoic acid supplementation reduces tumor volume and attenuates cachexia in a rat model of progressive non-metastasizing malignancy. JPEN J Parenter Enteral Nutr 26:291-297

Kalra P, Tigas S (2002). Regulation of lipolysis: natriuretic peptides and the development of cachexia. Int J Cardiol 85:125-132

Kotler DP (2000). Cachexia. Ann Intern Med 133:622-634

Lagana A, Duchaine T, Raz A, DesGroseillers L, Nabi IR (2000). Expression of autocrine motility factor/phosphohexose isomerase in Cos7 cells. Biochem Biophys Res Commun 273:213-218

Lange PH, Vessella RL (1998-9). Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev 17:331-336

Langen RC, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM (2001). Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. FASEB J 15:1169-1180

Lazarus DD, Destree AT, Mazzola LM, McCormack TA, Dick LR, Xu B, Huang JQ, Pierce JW, Read MA, Coggins MB, Solomon V, Goldberg AL, Brand SJ, Elliott PJ (1999). A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway. Am J Physiol 277:E332-E341

Lecker SH (2003). Ubiquitin-protein ligases in muscle wasting: multiple parallel pathways? Curr Opin Clin Nutr Metab Care 6:271-275

Li X, Choi SJ, Roodman GD, Guise TA, Chirgwin JM (2000). Autocrine motility factor (AMF) stimulates periosteal new bone formation. Calcified Tissue Internat 66(Suppl 1):S56 (Abstract O-26)

Lorite MJ, Thompson MG, Drake JL, Carling G, Tisdale MJ (1998). Mechanism of muscle protein degradation induced by a cancer cachectic factor. Br J Cancer 78:850-856

Lorite MJ, Smith HJ, Arnold JA, Morris A, Thompson MG, Tisdale MJ (2001). Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Br J Cancer 85:297-302

Matthys P, Dijkmans R, Proost P, Van Damme J, Heremans H, Sobis H, Billiau A (1991). Severe cachexia in mice inoculated with interferon-gamma-producing tumor cells. Int J Cancer 49:77-82

Matthys P, Billiau A (1997). Cytokines and cachexia. Nutrition 13:763-770

McDevitt H (2000). A new model for rheumatoid arthritis? Arthritis Res 2:85-89

McPherron AC, Lawler AM, Lee SJ (1997). Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387:83-90

Meazza R, Lollini PL, Nanni P, De Giovanni C, Gaggero A, Comes A, Cilli M, Di Carlo E, Ferrini S, Musiani P (2000). Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: effects on tumorigenicity, metastatic potential and immune response. Int J Cancer 87:574-581

Mitch WE, Price SR (2001). Transcription factors and muscle cachexia: is there a therapeutic target? Lancet 357:734-735

Mundy G (2001). Preclinical models of bone metastases. Semin Oncol 28(Suppl 11):2-8

Mundy GR (2002). Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593

Nagy T, Janossy T, Vizler C, Bohus K, Joo F, Vegh P, Duda E (1999). Pathophysiological effects of human TNF-alpha-producing tumor xenografts in immunosuppressed mice. APMIS 107:903-912

Nelson KA (2000). Modern management of the cancer anorexia-cachexia syndrome. Curr Oncol Rep 2:362-368

Norton JA, Moley JF, Green MV, Carson RE, Morrison SD (1985). Parabiotic transfer of cancer anorexia/cachexia in male rats. Cancer Res 45:5547-5552

Ogata E (2000). Parathyroid hormone-related protein as a potential target of therapy for cancer-associated morbidity. Cancer 88(S12):2909-2911

Ozaki Y, Oyama T, Kume S (1989). Exacerbation of toxic effects by endotoxin contamination of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 23:231-237

Parma M, Diament M, Garcia C, Piccinni E, Mondelo N, Klein S (1999). Mechanisms of paraneoplastic syndromes in mice bearing a spontaneous lung adenocarcinoma. Tumour Biol 20:304-311

Quinn LS, Anderson BG, Drivdahl RH, Alvarez B, Argiles JM (2002). Overexpression of interleukin-15 induces skeletal muscle hypertrophy in vitro: implications for treatment of muscle wasting disorders. Exp Cell Res 280:55-63

Read J, Pearce J, Li X, Muirhead H, Chirgwin J, Davies C (2001). The crystal structure of human phosphoglucose isomerase at 1.6 A resolution: implications for catalytic mechanism, cytokine activity and haemolytic anaemia. J Mol Biol 309:447-463

Roubenoff R, Roubenoff RA, Ward LM, Holland SM, Hellmann DB (1992). Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor. J Rheumatol 19:1505-1510

Ross JA, Fearon KC (2002). Eicosanoid-dependent cancer cachexia and wasting. Curr Opin Clin Nutr Metab Care 5:241-248

Schwartz MW, Morton GJ (2002). Keeping hunger at bay. Nature 418:595-597

Taylor WE, Bhasin S, Artaza J, Byhower F, Azam M, Willard DH Jr, Kull FC Jr, Gonzalez-Cadavid N (2001). Myostatin inhibits cell proliferation and protein synthesis in C2C12 muscle cells. Am J Physiol Endocrinol Metab 280:E221-228

Thompson MG, Palmer RM, Thom A, Mackie SC, Morrison KS, Harris CI (1996). Measurement of protein degradation by release of labelled 3-methylhistidine from skeletal muscle and non-muscle cells. J Cell Physiol 166:506-511

Tilignac T, Temparis S, Combaret L, Taillandier D, Pouch MN, Cervek M, Cardenas DM, Le Bricon T, Debiton E, Samuels SE, Madelmont JC, Attaix D (2002). Chemotherapy inhibits skeletal muscle ubiquitin-proteasome-dependent proteolysis. Cancer Res 62:2771-2777

Tisdale MJ (1998). New cachexic factors. Curr Opin Clin Nutr Metab Care 1:253-256

Tisdale MJ (2000). Metabolic abnormalities in cachexia and anorexia. Nutrition 16:1013-1014

Tisdale MJ (2001). Loss of skeletal muscle in cancer: biochemical mechanisms. Front Biosci. 6:D164-174

Tisdale MJ (2002). Cachexia in cancer patients. Nat Rev Cancer 2:862-871

Tisdale MJ (2002a). Biochemical mechanisms of cellular catabolism. Curr Opin Clin Nutr Metab Care 5:401-405

Todorov PT, Deacon M, Tisdale MJ (1997). Structural analysis of a tumor-produced sulfated glycoprotein capable of initiating muscle protein degradation. J Biol Chem 272:12279-12288

Tohgo A, Kumazawa E, Akahane K, Asakawa A, Inui A (2002). Anticancer drugs that induce cancer-associated cachectic syndromes. Expert Rev Anticancer Ther 2:121-129

Tsutsumi S, Hogan V, Nabi IR, Raz A (2003). Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblasts. Cancer Res 63:242-249.

Valorie AM (2000). Thalidomide. A new beginning. Cancer Pract 8:101-103

Watchorn TM, Waddell I, Dowidar N, Ross JA (2001). Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-(kappa)B and STAT3. FASEB J 15:562-564

Watchorn TM, Waddell I, Ross JA (2002). Proteolysis-inducing factor differentially influences transcriptional regulation in endothelial subtypes. Am J Physiol Endocrinol Metab 282:E763-769

Whitehouse AS, Smith HJ, Drake JL, Tisdale MJ (2001). Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res 61:3604-3609

Yates AJ, Boyce BF, Favarato G, Aufdemorte TB, Marcelli C, Kester MB, Walker R, Langton BC, Bonewald LF, Mundy GR (1992). Expression of human transforming growth factor alpha by Chinese hamster ovarian tumors in nude mice causes hypercalcemia and increased osteoclastic bone resorption. J Bone Miner Res 7:847-853

Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massagué J, Mundy GR, Guise TA (1999). TGF-$ signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103:197-206

Yoneda T, Alsina MA, Chavez JB, Bonewald L, Nishimura R, Mundy GR (1991a). Evidence that tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia, and leukocytosis in a human tumor in nude mice. J Clin Invest 87:977-985

Yoneda T, Alsina MM, Watatani K, Bellot F, Schlessinger J, Mundy GR (1991b). Dependence of a human squamous carcinoma and associated paraneoplastic syndromes on the epidermal growth factor receptor pathway in nude mice. Cancer Res 51:2438-2443

Zhou S, Kestell P, Tingle MD, Paxton JW (2002). Thalidomide in cancer treatment: a potential role in the elderly? Drugs Aging 19:85-100

Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, McPherron AC, Wolfman NM, Lee SJ (2002). Induction of cachexia in mice by systemically administered myostatin. Science 296:1486-1488

LEGENDS TO TABLE AND FIGURES

Table 1. Animals were implanted under anesthesia with osmotic minpumps as described in the original proposal. Pumps were loaded with 1 or 10 mg/ml sterile AMF/PGI stock in PBS. At 4 PM each day AMF/PGI was assayed on 10 ul of serum obtained from a retro-orbital blood sample obtained under anesthesia. Numbers immediately below the animal weights in g in each box are the raw PGI catalytic rate values. The results indicate that the minipumps failed to give significant increases in the serum concentrations of AMF/PGI, compared to those seen in patients with bone metastases or cachexia (Bodansky, 1954).

Figure 1. In the experimental protocol, animals were given the factor as sterile intraperitoneal (i.p.) injections of protein in PBS at 8 AM, noon, and 4 PM. Blood levels of PGI/AMF were measured at the 4 PM time. Animals were weighed at the indicated times. Animals were injected on days 1, 2, and 3.

Figure 2. Protocol was similar to that described under Figure 1. Mice received a single bolus i.p. injection of mouse AMF/PGI. 50 ul aliquots of blood were obtained retro-orbitally under anesthesia at the indicated times and assayed for PGI activity in 10 ul of serum.

Figure 3. Equivalent aliquots of column fractions of effluent from a Qiagen NiNTA column loaded with the cleared supernatant of E coli BL21DE3 pLysS cells treated with iPTG to induce expression of mouse PGI-H6 as described in the original proposal. 12.5% denaturing SDS Laemmli gel stained with Coomassie blue R250 and photographed with Kodak EDAS digital gel documentation syytem. Samples boiled with 2-mercaptoethanol reducing agent. Major band is the correct size for the anticipated subunit of 66 kDa.

Figure 4. Chemotaxis assays. RAW 264.7 and MOPC-5 are standard mouse monocyte/macrophage cell lines from the ATCC. Positive control, last lane of each panel, is media conditioned by the mouse osteocyte cell line MLO-Y4, developed by the collaborator in these experiments, Dr. Lynda Bonewald, University of Missouri Kansas City School of Dentistry.

8/13/02 Mouse AMF Pump Experiment

Pumps: Hold ~ 0.2 mL, delivery ~ 1uL/hour

	Mouse 1 PBS NC	Mouse 2 1mg/ml VC	Mouse 3 1mg/ml BC	Mouse 4 10mg/ml LC	Mouse 5 10mg/ml RC
Day 0	34.95g	31.94g	40.25g	34.60g	32.50g
Day 1	33.60g 0.1884Δ/min	31.80g 0.1207Δ/min	39.30g 0.0719Δ/min	35.55g 0.2799Δ/min	31.45g 0.2304Δ/min
Day 2	33.74g 0.1341Δ/min	32.33g hemolysed	40.00g hemolysed	34.60g 0.2346Δ/min	31.81g hemolysed
Day 3	33.13g 0.1983Δ/min	32.50g 0.1712Δ/min	39.63g 0.0759Δ/min	34.30g 0.1486Δ/min	32.30g 0.1426Δ/min
Day 4	32.98g 0.1335Δ/min	33.12g 0.1136Δ/min	38.76g 0.0712Δ/min	35.30g 0.2142Δ/min	32.65gg 0.2345Δ/min
Day 7	33.80g 0.1129Δ/min	33.27g 0.1256Δ/min	39.75g 0.0750Δ/min	33.70g 0.2244Δ/min	32.40g 0.2822Δ/min

Table 1



Serum AMF Activity		
	Mouse 1	Mouse 2
Baseline	17U/ml	11U/ml
Day 1	1564U/ml	1800U/ml
Day 2	2900U/ml	1550U/ml
Day 3	1488U/ml	1690U/ml
Day 4	4U/ml	10U/ml

Figure 1

Clearance of I.P. PGI



Figure 2

Mouse PGI-H_6 Purification



Figure 3


Chemotaxis assay (RAW 264.7 cells)
No of cells attached to bottom of transwell
160
140
120
100
80
60
40
20
0
con
0.1ng/ml
1ng/ml
10ng/ml
100ng/ml
MLO-Y4 10% CM
mPGI (ng/ml)


Chemotaxis assay (MOCP-5 cells)
No of cells attached to bottom of transwell
400
350
300
250
200
150
100
50
0
con
0.1ng/ml
1ng/ml
10ng/ml
100ng/ml
MLO-Y4 10% CM
mPGI (ng/ml)

Figure 4

APPENDIX

Copy of published paper: Davies C, Muirhead H, Chirgwin J (2003). The structure of human phosphoglucose isomerase complexed with a transition-state analogue. Acta Crystallogr D Biol Crystallogr 59:1111-1113

Acta Crystallographica Section D
Biological Crystallography
ISSN 0907-4449

The structure of human phosphoglucose isomerase complexed with a transition-state analogue

Christopher Davies,[a]* Hilary Muirhead[b] and John Chirgwin[c]

[a]Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA, [b]School of Medical Sciences, University of Bristol, Bristol BS8 1TD, England, and [c]Department of Medicine, University of Virginia, Charlottesville, VA 22908, USA

Correspondence e-mail: davies@musc.edu

Phosphoglucose isomerase (PGI) is a workhorse enzyme of carbohydrate metabolism that interconverts glucose 6-phosphate and fructose 6-phosphate. Outside the cell, however, the protein appears to function as a cytokine. A crystal structure of human PGI bound with 5-phosphoarabinonate, a strong inhibitor that mimics the *cis*-enediol(ate) intermediate of the reaction, has been determined at 2.5 Å resolution. The structure helps to confirm the assignment of Glu357 as the base catalyst in the isomerase reaction.

Received 19 February 2003
Accepted 1 April 2003

PDB Reference: phosphoglucose isomerase–5-phosphoarabinonate, 1nuh, r1nuhsf.

1. Introduction

Phosphoglucose isomerase (EC 5.3.1.9) is a workhorse enzyme of sugar metabolism. It catalyses the second step of glycolysis, the interconversion of glucose 6-phosphate (G6P) and fructose 6-phosphate (F6P), by transfer of a proton between the C2 position of G6P and C1 of F6P (Rose, 1975). Recent crystal structures of the enzyme have led to proposals that Glu357 is the active-site base responsible for this transfer (Lee *et al.*, 2001; Read *et al.*, 2001) and that either His388 or Lys518 catalyses the ring-opening of the sugar substrate (Davies & Muirhead, 2003; Lee *et al.*, 2001). The human enzyme is of medical interest because mutations in this enzyme lead to non-spherocytic haemolytic anaemia (Baughan *et al.*, 1968) and because high levels of PGI activity are measured in the sera of patients with certain cancers (Baumann *et al.*, 1990).

Interest in PGI has grown following the discoveries that it manifests cytokine function in a wide variety of cellular activities (Gurney *et al.*, 1986; Watanabe *et al.*, 1996; Xu *et al.*, 1996) and appears to be an antigen in rheumatoid arthritis (Matsumoto *et al.*, 1999) and sperm agglutination (Yakirevich & Naot, 2000). To what extent the enzymatic properties of PGI overlap with its cytokine functions remains unclear.

Here, we present the crystal structure of human PGI bound to a transition-state analogue, 5-phosphoarabinonate (PAB), solved at 2.5 Å resolution. Along with equivalent structures obtained from pig and rabbit sources (Davies & Muirhead, 2002; Jeffery *et al.*, 2001), it supports the hypothesis that Glu357 is the base catalyst in the reaction mechanism.

2. Experimental

Human PGI was purified and crystallized as described previously (Read *et al.*, 2001) except that 5 m*M* PAB was included in the protein drops. The resulting crystals were of the same morphology as native crystals but diffracted X-rays less well. After stabilization in a solution containing 2.1 *M* ammonium sulfate, 100 m*M* Tris–HCl pH 8.5 and 30% glycerol, the crystals were flash-frozen to 100 K. Data were collected with an R-AXIS IV^{++} detector positioned at a crystal-to-detector distance of 160 mm and mounted on an RU3-HBR X-ray generator (Rigaku-MSC) fitted with Osmic mirror optics. The crystals belonged to space group $P4_32_12$, with unit-cell parameters $a = b = 94.4$, $c = 137.1$ Å. A total of 173 frames were collected in 0.5° oscillations to ensure high redundancy, with an exposure time of 5 min per frame. The data were processed using *d*TREK* (Pflugrath, 1999). The starting model for refinement was the 1.6 Å resolution structure of human PGI (Read *et al.*, 2001) from which a bound sulfate and all waters molecules had been removed. After initial refinement using *X-PLOR* (Brünger, 1992), both $2(|F_o| - |F_c|)$ and $(|F_o| - |F_c|)$ electron-density maps clearly showed the PAB molecule bound at the active site. After a molecule PAB was fitted to the density, subsequent rounds of refinement used *REFMAC* (Murshudov *et al.*, 1997). The final model is numbered 1–555 and includes one PAB molecule, six sulfate mole-

Table 1
X-ray diffraction data and refinement statistics.

Values in parentheses are for the outer resolution shell.

Data collection	
Resolution range (Å)	50–2.5 (2.59–2.5)
R_{merge}† (%)	12.8 (25.4)
Redundancy	6.9 (6.8)
Completeness (%)	98.4 (99.8)
$\langle I\rangle/\langle\sigma(I)\rangle$	5.7 (3.1)
Refinement	
Resolution range (Å)	50.0–2.5
σ cutoff applied	0.0
Total No. of reflections	21468
Reflections used in R_{free} (%)	5.0
No. of non-H protein atoms	4424
No. of sulfate molecules	6
No. of water molecules	109
R factor (%)	21.7
R_{work} (%)	21.4
R_{free} (%)	26.8
R.m.s. deviations from ideal stereochemistry	
Bond lengths (Å)	0.011
Bond angles (°)	1.48
B factors (Å^2)	
Overall B factor	25.16
Mean B factor (main chain)	24.55
R.m.s. deviation in main-chain B factor	0.390
Mean B factor (side chains and waters)	25.72
R.m.s. deviation in side-chain B factors	1.454
Ramachandran plot statistics (%)	
Residues in most favoured region	88.8
Residues in additionally allowed regions	10.8
Residues in generously allowed regions	0.4
Residues in disallowed regions	0.0

† $R_{merge} = \sum|I_i - I_m|/\sum I_i$, where I_i is the intensity of the measured reflection and I_m is the mean intensity of all symmetry-related reflections.

cules (arising from the crystallization solution) and 109 water molecules. The data-collection and refinement statistics are shown in Table 1.

3. Results and discussion

3.1. Structure description

PGI has been solved from a variety of mammalian sources and from *Bacillus stearothermophilus* in both native and inhibitor-bound forms (see, for example, Davies & Muirhead, 2002; Jeffery *et al.*, 2000; Read *et al.*, 2001; Sun *et al.*, 1999). The protein architecture is essentially identical in mammalian PGIs and is highly similar in the enzyme from *B. stearothermophilus*. The structure comprises two domains, termed large and small, where each domain consists of a central β-sheet surrounded by α-helices. The active site is located in a crevice between the large and small domains, near the subunit boundary. The enzyme form of human PGI exists as a dimer (Tilley *et al.*, 1974), but since it crystallizes as a monomer in the asymmetric unit a symmetry operation is required to generate the dimer. The active site comprises residues that are likely to play a role in the catalytic mechanism, including Glu357, Arg272, His388 and Lys518. One of these residues, His388, is contributed by the adjacent monomer.

3.2. Ligand binding

PAB is a competitive inhibitor of PGI that is believed to mimic the *cis*-enediolate intermediate of the catalytic reaction (Chirgwin & Noltmann, 1975). Our structure of human PGI in complex with PAB helps to further resolve the ambiguity regarding the binding mode of this inhibitor. The PAB molecule is bound to the active site in essentially an identical manner to that seen in equivalent complexes of PGI from rabbit (Jeffery *et al.*, 2001) and pig (Davies & Muirhead, 2002), but the opposite of that seen in a complex with PGI from *B. stearothermophilus* (Chou *et al.*, 2000) (Fig. 1). As expected, the sulfate molecule that was observed in the active site of the native structure (Read *et al.*, 2001) has been displaced by the phosphate group of the PAB inhibitor. The phosphate group is oriented by the same cluster of serine and threonine side chains (Ser209, Thr211, Thr214 and Ser159) as well as the amide N atoms of Lys210 and Thr211 and by one water molecule to Thr217. Both the C2 and C3 hydroxyls (equivalent to C3 and C4 of the substrate) are within hydrogen-bonding distance of the amide group of Gly158. This region of the inhibitor lies close to the turn formed by Gly157 and Gly158 and the absence of side chains in these positions facilitates a closer binding of the substrate. The monitoring of these two hydroxyls by Gly158 probably contributes to the high specificity of PGI for its sugar substrates. One of the side-chain O atoms of Glu357 lies close to O1A and C1 of PAB as well as to the guanidinium group of Arg272. This arrangement suggests that Glu357 is best placed to abstract a proton from the C2 and C1 positions of G6P and F6P, respectively, as proposed recently (Lee *et al.*, 2001; Read *et al.*, 2001), and that the positive charge of Arg272 may stabilize the negative charge of the *cis*-enediolate intermediate. Lys518 and His388 both contact O4, which is equivalent to the ring oxygen of the substrate, and Lys518 also contacts O5. Either or both of these residues may participate in ring opening.

3.3. Comparison with native human PGI

Two structures of human PGI have been published. The first of these contains a sulfate in the active site that appears to mimic the phosphate moiety of the substrate (Read *et al.*, 2001), whereas the second structure is free of ligands and so better represents the true native state of the enzyme (Tanaka *et al.*, 2002). Comparisons of the sulfate-bound structure with a ligand-free structure of rabbit PGI suggested that elements of the small domain shift from an 'open' to 'closed' conformation upon binding sulfate (Read *et al.*, 2001). The hypothesis that the sulfate moiety was mimicking the sugar phosphate is confirmed by the human PAB-bound structure, in which the same region of the small domain is seen in the 'closed' conformation. In contrast, all four molecules present in the



Figure 1
5-Phosphoarabinonate bound to human phosphoglucose isomerase at 2.5 Å resolution. A stereo picture of the active-site region, showing the $2(|F_o| - |F_c|)$ electron density of the bound inhibitor, contoured in blue at 1σ. The active-site residues and inhibitor molecules are shown in ball-and-stick form. The inhibitor is coloured red. This figure was prepared using *PyMOL* (DeLano, 2002).



Figure 2
The shift of α23 caused by the binding of 5-phosphoarabinonate. Shown is a backbone superimposition of the sulfate-bound human structure (Read *et al.*, 2001) coloured in orange and the PAB-bound structure in green. Important residues are shown in ball-and-stick representation, in which the bonds are coloured the same as the backbone. Note the rotation of the carboxylate of Glu357 and the slight shift of the adjacent residue, Gln353. For clarity, only helices 23 and 17 are shown. This figure was prepared using *MOLSCRIPT* (Kraulis, 1991).

structure of a ligand-free human PGI are seen in the 'open' conformation (Tanaka *et al.*, 2002).

The only other structural difference of significance is the shift of the N-terminal half of helix α23 (residues 512–520) toward the active site which occurs in the PAB-bound structure but in neither of the human native structures (Fig. 2). The same movement of α23 has been seen in the pig and rabbit homologues of PGI (Arsenieva & Jeffery, 2002; Davies & Muirhead, 2002, 2003). The shift of Lys518 toward the active site and its close proximity to the ring oxygen is concordant with a role for this residue in ring opening. Interestingly, the carboxylate group of Glu357 rotates by approximately 90° to align more closely with the carboxylate on the PAB molecule. In the case of the true substrate, a similar repositioning would enhance the ability of Glu357 to abstract a proton from the C1/C2 positions (Fig. 2).

4. Conclusion

The structure of human PGI bound to 5-phosphoarabinonate further establishes Glu357 as the best candidate for base catalyst, as proposed recently (Lee *et al.*, 2001; Read *et al.*, 2001), supplanting earlier suggestions that His388 was responsible (Chou *et al.*, 2000; Jeffery *et al.*, 2000). Instead, His388 is likely to be the acid catalyst for ring opening. The close proximity of Lys518 to the ring oxygen and its shift towards the active site upon PAB binding suggest that it too has a role in the mechanism of ring opening. PGI is becoming increasingly better characterized as an enzyme, but much remains to be elucidated regarding its cytokine function.

The authors wish to thank Klaus Schnackerz for the kind gift of the 5-phosphoarabinonate used in this study. This research was supported by grants from the US Army (DAMD17-98-1-8245 and DAMD17-02-1-0586) to JMC.

References

Arsenieva, D. & Jeffery, C. (2002). *J. Mol. Biol.* **323**, 77–84.
Baumann, M., Kappl, A., Lang, T., Brand, K., Siegfried, W. & Paterok, E. (1990). *Cancer Invest.* **8**, 351–356.
Baughan, M. A., Valentine, W. N., Paglia, D. E., Ways, P. O., Simons, E. R. & DeMarsh, Q. B. (1968). *Blood*, **32**, 236–249.
Brünger, A. T. (1992). *X-PLOR. Version 3.1. A System for X-ray Crystallography and NMR.* Yale University, New Haven, CT, USA.
Chirgwin, J. M. & Noltmann, E. A. (1975). *J. Biol. Chem.* **250**, 7272–7276.
Chou, C.-C., Sun, Y.-J., Meng, M. & Hsiao, C.-D. (2000). *J. Biol. Chem.* **275**, 23154–23160.
Davies, C. & Muirhead, H. (2002). *Proteins Struct. Funct. Genet.* **49**, 577–579.
Davies, C. & Muirhead, H. (2003). *Acta Cryst.* D**59**, 453–465.
DeLano, W. L. (2002). *The PyMOL Molecular Graphics System*, http://pymol.sourceforge.net.
Gurney, M. E., Apatoff, B. R., Spear, G. T., Baumel, M. J., Antel, J. P., Bania, M. B. & Reder, A. T. (1986). *Science*, **234**, 574–581.
Jeffery, C. J., Bahnson, B. J., Chien, W., Ringe, D. & Petsko, G. A. (2000). *Biochemistry*, **39**, 955–964.
Jeffery, C. J., Hardre, R. & Salmon, L. (2001). *Biochemistry*, **40**, 1560–1566.
Kraulis, P. J. (1991). *J. Appl. Cryst.* **24**, 946–950.
Lee, J. H., Chang, K. Z., Patel, V. & Jeffery, C. J. (2001). *Biochemistry*, **40**, 7799–7805.
Matsumoto, I., Staub, A., Benoist, C. & Mathis, D. (1999). *Science*, **286**, 1732–1735.
Murshudov, G. N., Vagin, A. A. & Dodson, E. J. (1997). *Acta Cryst.* D**53**, 240–255.
Pflugrath, J. W. (1999). *Acta Cryst.* D**55**, 1718–1725.
Read, J., Pearce, J., Li, X., Muirhead, H., Chirgwin, J. & Davies, C. (2001). *J. Mol. Biol.* **309**, 447–464.
Rose, I. A. (1975). *Adv. Enzymol. Relat. Areas Mol. Biol.* **43**, 491–517.
Sun, Y. J., Chou, C. C., Chen, W. S., Wu, R. T., Meng, M. & Hsiao, C. D. (1999). *Proc. Natl Acad. Sci. USA*, **96**, 5412–5417.
Tanaka, N., Haga, A., Uemura, H., Akiyama, H., Funasaka, T., Nagase, H., Raz, A. & Nakamura, K. (2002). *J. Mol. Biol.* **318**, 985–997.
Tilley, B. E., Gracy, R. W. & Welch, S. G. (1974). *J. Biol. Chem.* **249**, 4571–4579.
Watanabe, H., Takehana, K., Date, M., Shinozaki, T. & Raz, A. (1996). *Cancer Res.* **56**, 2960–2963.
Xu, W., Seiter, K., Feldman, E., Ahmed, T. & Chiao, J. W. (1996). *Blood*, **87**, 4502–4506.
Yakirevich, E. & Naot, Y. (2000). *Biol. Reprod.* **62**, 1016–1023.